Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s mGlu2/3 Agonist Fails In Phase II For Schizophrenia – But So Does Zyprexa

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly vows to do another Phase II in effort to replicate an earlier study that showed efficacy for the novel schizophrenia drug over placebo.
Advertisement

Related Content

Lilly Pulls The Plug On Next-Gen Antipsychotic
Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
Lilly’s Intended Successor To Zyprexa Faces Uncertain Future After Phase III Failure
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
Troubled Biotechs: Intercytex, Vanda, Advanced Life Sciences
Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate
Merck, Addex Sign $700 Million Deal For Novel Schizophrenia Candidate

Topics

Advertisement
UsernamePublicRestriction

Register

PS069206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel